Tomer Mark, M.D.

Medical Oncology
Tomer Mark

After completing fellowship at New York Presbyterian Hospital - Weill Cornell Medical Center under the mentorship of Dr. Ruben Niesvizky, I have joined the Center for Lymphoma and Myeloma as a full-time clinician with a focus on clinical and translational research. I hope to provide excellent care to persons with multiple myeloma and other plasma cell disorders in the context of advancement of the clinical knowledge of these diseases. Our approach at the practice is to improve upon the standard of care and provide a broad range individualized treatment for each unique patient, be it from oral treatments, to chemotherapeutics, to stem cell transplant.

Our goal at the myeloma practice at Weill Cornell is to one day find a cure. We are working diligently and making progressive strides towards this end; currently, we are bringing the latest advancements to patients with plasma cell disorders into regular clinical practice.

Dr. Tomer Mark is an assistant professor of medicine at the Weill Cornell Medical College. He specializes in seeing patients with multiple myeloma and other plasma cell disorders, with a focus on stem cell transplantation and clinical trials.

Dr. Mark grew up in New York where he attended public school. He graduated from the Bronx High School of Science in 1994. Dr. Mark graduated from Yale University in 1998 and went to medical school at the State University of New York at Stony Brook, where he graduated with a medical degree with recognition in research. He did his Internal Medicine Residency training at Beth Israel Deaconess Medical Center, Boston, MA. and completed his Hematology and Medical Oncology Fellowship at New York Presbyterian Hospital: New York Weill Cornell Center in June 2008.

Dr. Mark is currently enrolled in the Master's Program in Clinical Investigation at the Weill Cornell School of Graduate Sciences in addition to sharing clinical responsibilities at the Multiple Myeloma Center. He currently lives in Queens, NY with his wife and two dogs.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [PPO]
  • AETNA [HMO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Health Plan
  • CIGNA
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup
  • Medicare [Medicare]
  • Oxford Health Plans [Freedom]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Rockefeller University - CoreSource
  • United Empire
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • United Health Care

Publications

Peer Reviewed Articles:

1) Shi H., Djikeng A., Mark T., Wirtz E., Tschudi C., Ullu E. Genetic interference in Trypanosoma

brucei by heritable and inducible double-stranded RNA. RNA. 6(7):1069-76, July 2000.

2) Ruben Niesvizky, Tara Naib, Paul Christos, David Jayabalan, Jessica R Furst, Jessica Jalbrzikowski, Faiza Zafar, Tomer Mark, Richard Lent, Roger Pearse, Scott Ely, John Leonard, Madhu Mazumdar, Selina Chen-Kiang, Morton Coleman. Lenalidomide Induced Myelosuppression is Associated with Renal Dysfunction: Toxicity Evaluation of Treatment Naïve Patients Undergoing Front-Line Lenalidomide and Dexamethasone Therapy.

Br J Haematology. 2007 Sep;138(5):640-3.

3) Niesvizky, R;., Martínez-Baños, D., Jalbrzikowski J., Christos P., Furst J., DeSancho M., Mark T., Pearse R., Mazumdar M., Zafar F., Pekle K., Rambo A., Leonard J., Jayabalan D., Coleman M. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia and Lymphoma. 2007 Dec;48(12):2330-7.

4) Ruben Niesvizky, David S. Jayabalan, Paul J. Christos, Jessica R. Furst, Tara Naib, Scott Ely, Jessica Jalbrzikowski, Roger N. Pearse, Faiza Zafar, Karen Pekle, Richard Lent, Tomer Mark, Hearn J. Cho, Tsiporah Shore, Jeffrey Tepler, John Harpel, Michael Schuster, Susan Mathew, John P. Leonard, Madhu Mazumdar, Selina Chen-Kiang, and Morton Coleman.

BiRD (Biaxin®[clarithromycin]/Revlimid®[lenalidomide]/dexamethasone) Combination Therapy Results in High Complete and Overall Response Rates in Treatment-Naïve Symptomatic Multiple Myeloma. Blood. 2007. In press, Epub ahead of print PMID: 17989313

5) Tomer Mark, Ruben Niesvizky. Treatment of multiple myeloma and myelodysplastic syndromes with immunomodulatory derivates. US Oncological Disease. 2008. Accepted for publication.

Abstracts:

1) Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy On Stem Cell Collection In Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Tomer Mark, David Jayabalan, Roger N Pearse, Jessica Stern, Jessica Furst, April Rambo, John Harpel, Tsiporah Shore, Michael Schuster, John P Leonard, Paul J Christos, Morton Coleman, and Ruben Niesvizky. Poster Presentation at the American Society of Hematology Meeting, 2007.

2) Atypical Serum Immunofixation Pattern (ASIP) Development During Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Tomer Mark, David Jayabalan, Roger N Pearse, Y. Lynn Wang, Richard Lent, Paul J Christos, Joong W Lee, Yashpal P Agrawal, Susan Matthews, Scott Ely, Madhu Mazumdar, Ethel Cesarman, April Rambo, John P Leonard, Morton Coleman, Selina Chen-Kiang, and Ruben Niesvizky, MD. Poster Presentation at the American Society of Hematology Meeting, 2007.

3) Stem cell collection prior to autologous stem cell transplantation is improved by cyclophosphamide in lenalidomide-treated patients with multiple myeloma.

Tomer Mark, David Jayabalan, Roger N Pearse, Jessica Stern, Jessica Furst, April Rambo, John Harpel, Tsiporah Shore, Michael Schuster, John P Leonard, Paul J Christos, Morton Coleman, and Ruben Niesvizky. Poster Presentation at the Bone Marrow Transplantation Tandem Meetings. 2008.

Honors and Awards

Fifth Annual Department of Medicine Fellows Award Winner - 2007